Literature DB >> 8733488

Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic.

K Muhdi1, F P Edenborough, L Gumery, S O'Hickey, E G Smith, D L Smith, D E Stableforth.   

Abstract

BACKGROUND: There has been increasing concern since 1979 about the emergence of Pseudomonas cepacia (Burkholderia cepacia) in patients with cystic fibrosis in the UK and elsewhere. Colonisation of the sputum has been shown to be associated with increased morbidity and mortality. Evidence suggests person to person transmission and some centres have segregated those colonised with B cepacia from other patients with cystic fibrosis. The outcome of patients colonised by B cepacia has been studied, together with the effects of strict segregation.
METHODS: The outcome in 18 patients with sputum colonised by B cepacia was compared with that in age, sex, and severity matched controls with no evidence of B cepacia colonisation by a retrospective case note study.
RESULTS: No difference between cases or controls were found in the 24 month period prior to colonisation by B cepacia in lung function, number of days in hospital, or outpatient visits. Colonisation led to an increased rate of loss of lung function and utilisation of hospital services. There was an increase in the numbers of transplants and deaths amongst the cases. Since 1992 there have been only three new cases of B cepacia colonisation and the incidence and prevalence of the organism has fallen dramatically since segregation commenced.
CONCLUSIONS: B cepacia appears to be linked to the decline in colonised individuals. There was no evidence that colonisation occurred in patients declining for other reasons. B cepacia colonisation confers a worse prognosis than Pseudomonas aeruginosa alone. Segregation appears to limit the spread of the organism from infected individuals to other patients with cystic fibrosis.

Entities:  

Mesh:

Year:  1996        PMID: 8733488      PMCID: PMC1090671          DOI: 10.1136/thx.51.4.374

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  14 in total

1.  Transmission of Pseudomonas cepacia among cystic fibrosis patients.

Authors:  L Millar-Jones; A Paull; Z Saunders; M C Goodchild
Journal:  Lancet       Date:  1992-08-22       Impact factor: 79.321

2.  Pseudomonas cepacia in inpatients with cystic fibrosis.

Authors:  J W Nelson; C J Doherty; P H Brown; A P Greening; M E Kaufmann; J R Govan
Journal:  Lancet       Date:  1991-12-14       Impact factor: 79.321

3.  Pseudomonas cepacia in cystic fibrosis.

Authors:  D E Stableforth; D L Smith
Journal:  Thorax       Date:  1994-07       Impact factor: 9.139

4.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.

Authors:  A Isles; I Maclusky; M Corey; R Gold; C Prober; P Fleming; H Levison
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

5.  Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission.

Authors:  D L Smith; L B Gumery; E G Smith; D E Stableforth; M E Kaufmann; T L Pitt
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

Review 6.  Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology.

Authors:  D A Goldmann; J D Klinger
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

7.  Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist.

Authors:  M J Thomassen; C A Demko; J D Klinger; R C Stern
Journal:  Am Rev Respir Dis       Date:  1985-05

8.  Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients.

Authors:  L O Lewin; P J Byard; P B Davis
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

9.  Pseudomonas cepacia in lung transplant recipients with cystic fibrosis.

Authors:  G I Snell; A de Hoyos; M Krajden; T Winton; J R Maurer
Journal:  Chest       Date:  1993-02       Impact factor: 9.410

10.  Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis.

Authors:  J J Lipuma; K A Marks-Austin; D S Holsclaw; G B Winnie; P H Gilligan; T L Stull
Journal:  Pediatr Infect Dis J       Date:  1994-08       Impact factor: 2.129

View more
  21 in total

1.  Enhanced susceptibility to pulmonary infection with Burkholderia cepacia in Cftr(-/-) mice.

Authors:  U Sajjan; G Thanassoulis; V Cherapanov; A Lu; C Sjolin; B Steer; Y J Wu; O D Rotstein; G Kent; C McKerlie; J Forstner; G P Downey
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Cystic fibrosis, a Burkholderia cenocepacia chest wall abscess and rapid clinical deterioration.

Authors:  N J Simmonds; K M Gyi
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

3.  Persistent airway colonization with Alcaligenes xylosoxidans in two brothers with cystic fibrosis.

Authors:  H Peltroche-Llacshuanga; H Peltroche-Llacsahuanga; H Kentrup; G Haase
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-02       Impact factor: 3.267

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 5.  Should patients with cystic fibrosis infected with Burkholderia cepacia undergo lung transplantation?

Authors:  A K Webb; J Egan
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

6.  Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre.

Authors:  M J Ledson; M J Gallagher; M Jackson; C A Hart; M J Walshaw
Journal:  Thorax       Date:  2002-02       Impact factor: 9.139

Review 7.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

Review 8.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

9.  Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis.

Authors:  M R Shreve; S Butler; H J Kaplowitz; H R Rabin; D Stokes; M Light; W E Regelmann
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 10.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.